Anti-CD3/CD20 bispecific antibodies as salvage therapy after CAR-T failure in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysis
Annals of Hematology · 12.05.2026 · 105 (7)
DOI: 10.1007/s00277-026-07025-w ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Annals of Hematology, online erschienen am 12.05.2026. Verfasst von Ning Yuan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Salvage Therapy, CD3 Complex, Immunotherapy, Adoptive. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Public Welfare Research Project of Novel Cancer Supportive Treatment, China Health & Medical Development Foundation, Chinese Anti-Cancer Association.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, China.
- Department of Oncology, Sun Yat-Sen University The First Affiliated Hospital, Guangzhou, 510080, China.
- Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China. liupp@sysucc.org.cn.
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, 510060, China. liupp@sysucc.org.cn.
- Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China. lizhm@sysucc.org.cn.
Förderung
- Public Welfare Research Project of Novel Cancer Supportive Treatment
- China Health & Medical Development Foundation
- Chinese Anti-Cancer Association
Zitieren
APA
Yuan, N., Chen, C., Xu, F., Yang, H., Wang, Y., Liu, P., Li, Z., & Sun, P. (2026). Anti-CD3/CD20 bispecific antibodies as salvage therapy after CAR-T failure in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysis. Annals of Hematology, 105(7). https://doi.org/10.1007/s00277-026-07025-w
Vancouver
Yuan N, Chen C, Xu F, Yang H, Wang Y, Liu P, et al. Anti-CD3/CD20 bispecific antibodies as salvage therapy after CAR-T failure in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysis. Annals of Hematology. 2026;105(7). doi:10.1007/s00277-026-07025-w
BibTeX
@article{Yuan2026,
author = {Yuan, Ning and Chen, Cui and Xu, Fei and Yang, Hang and Wang, Yu and Liu, Panpan and Li, Zhiming and Sun, Peng},
title = {Anti-CD3/CD20 bispecific antibodies as salvage therapy after CAR-T failure in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysis},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {7},
doi = {10.1007/s00277-026-07025-w}
}
EUVIMED